The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

Thumbnail
View/Open
Date
2019-12
ICR Author
Author
O'Sullivan, JM
Hamblin, A
Yap, C
Fox, S
Boucher, R
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/3385
DOI
Collections
Subject
Humans
Hydroxyurea
Pyrazoles
Disease-Free Survival
Survival Rate
Risk Factors
Drug Resistance
Female
Male
Thrombocythemia, Essential
Research team
Clinical Trials & Statistics Unit
Language
eng
License start date
2019-12
Citation
Blood, 2019, 134 (23), pp. 2107 - 2111